Treatment of Alzheimer – Alzheimer’s Vaccine
A major effort has made several research groups to synthesize a vaccine available to prevent Alzheimer’s disease (AD).
In simple terms, the idea is to create in a laboratory, a protein that is very similar to proteins that normally are deposited in the brain of the sick patient and eventually cause the symptoms of dementia.
By exposing a healthy individual and any risk factors, such as a history of having close relatives with the EA, it creates antibodies created in the lab and also with proteins that are characteristic of AD.
This would prevent therefore, protein synthesis and deposition years later that will cause the first symptoms of dementia.
Already there have been many scientific studies and is expected to close in the future hopefully be approved this vaccine, which will undoubtedly be a great addition to the treatment of AD.
Galantamine: Another Alternative for the Treatment of Alzheimer
Soon more will be available in the Chilean market the drug Galantamine (Razadyne ER in the U.S.) and is part of the therapeutic alternatives for Alzheimer’s disease with early or intermediate.
Its mechanism of action is blocking an enzyme called Acetilcolinesteras, resulting in an increased concentration of acetylcholine in the brain and thus, improved part of the disease symptoms.
Route of administration is oral, and there is a prolonged-release (ER Razadyne) and conventional one. This drug, which in recent years is already being used in Europe, will enter into competition with other therapeutic alternatives that are already in the market for Chile: Donepezil, Rivastigmine, Memantine, and Cerebrolysin (also soon to be released to the market).
Posted in 
Tags: